Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 35 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 10981855

    Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

    PTC THERAPEUTICS, INC. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  2. US 10980861

    Glucokinase activator compositions for the treatment of diabetes

    VTV THERAPEUTICS LLC · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  3. US 10980780

    Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

    NEUROSENSE THERAPEUTICS LTD. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  4. US 10980746

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  5. US 10980756

    Methods of treatment

    First Wave Bio, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  6. US 10980770

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  7. US 10973841

    Compositions for the treatment of skin conditions

    FORTE SUBSIDIARY, INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  8. US 10973758

    Methods of eye treatment using therapeutic compositions containing dipyridamole

    O.D. Ocular Discovery Ltd. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  9. US 10973764

    Neuroprotective liposome compositions and methods for treatment of stroke

    The Board of Regents of the University of Texas System · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  10. US 10968166

    4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

    PTC THERAPEUTICS, INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

  11. US 10968231

    Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

    Takeda Pharmaceutical Company Limited · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

  12. US 10968278

    Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

  13. US 10959952

    Use of exosomes for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  14. US 10961305

    Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

    Mereo Biopharma 3 Limited · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  15. US 10961298

    Monoclonal antibodies for treatment of microbial infections

    The Government of the United States, represented by the Secretary of the Army · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  16. US 10959988

    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  17. US 10960045

    Methods and compositions for the treatment of epidermolysis bullosa

    Compass Therapeutics LLC · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  18. US 10961267

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Theravance Biopharma R&D IP, LLC · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  19. US 10954198

    Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

    United Kingdom Research and Innovation · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  20. US 10952980

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  21. US 10946033

    2′-substituted-N6-substituted purine nucleotides for RNA virus treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  22. US 10947302

    Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them

    The Regents of the University of California · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  23. US 10945988

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  24. US 10941128

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.